ZIVO Bioscience (ZIVO) Competitors $15.57 -0.14 (-0.88%) As of 10:53 AM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsTrendsBuy This Stock ZIVO vs. GOSS, CADL, OCGN, TSVT, TERN, PVLA, INZY, LFCR, AVIR, and NGNEShould you be buying ZIVO Bioscience stock or one of its competitors? The main competitors of ZIVO Bioscience include Gossamer Bio (GOSS), Candel Therapeutics (CADL), Ocugen (OCGN), 2seventy bio (TSVT), Terns Pharmaceuticals (TERN), Palvella Therapeutics (PVLA), Inozyme Pharma (INZY), Lifecore Biomedical (LFCR), Atea Pharmaceuticals (AVIR), and Neurogene (NGNE). These companies are all part of the "pharmaceutical products" industry. ZIVO Bioscience vs. Gossamer Bio Candel Therapeutics Ocugen 2seventy bio Terns Pharmaceuticals Palvella Therapeutics Inozyme Pharma Lifecore Biomedical Atea Pharmaceuticals Neurogene ZIVO Bioscience (NASDAQ:ZIVO) and Gossamer Bio (NASDAQ:GOSS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, community ranking, analyst recommendations, earnings, risk, profitability and media sentiment. Does the media prefer ZIVO or GOSS? In the previous week, Gossamer Bio had 7 more articles in the media than ZIVO Bioscience. MarketBeat recorded 7 mentions for Gossamer Bio and 0 mentions for ZIVO Bioscience. Gossamer Bio's average media sentiment score of 0.61 beat ZIVO Bioscience's score of 0.00 indicating that Gossamer Bio is being referred to more favorably in the news media. Company Overall Sentiment ZIVO Bioscience Neutral Gossamer Bio Positive Which has stronger earnings & valuation, ZIVO or GOSS? ZIVO Bioscience has higher earnings, but lower revenue than Gossamer Bio. Gossamer Bio is trading at a lower price-to-earnings ratio than ZIVO Bioscience, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZIVO Bioscience$15.85K3,746.12-$7.78M-$4.93-3.16Gossamer Bio$124.59M2.14-$179.82M-$0.23-5.11 Do analysts rate ZIVO or GOSS? Gossamer Bio has a consensus price target of $7.75, indicating a potential upside of 559.57%. Given Gossamer Bio's stronger consensus rating and higher probable upside, analysts clearly believe Gossamer Bio is more favorable than ZIVO Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ZIVO Bioscience 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Gossamer Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, ZIVO or GOSS? ZIVO Bioscience has a beta of 0.03, meaning that its stock price is 97% less volatile than the S&P 500. Comparatively, Gossamer Bio has a beta of 1.82, meaning that its stock price is 82% more volatile than the S&P 500. Does the MarketBeat Community prefer ZIVO or GOSS? Gossamer Bio received 58 more outperform votes than ZIVO Bioscience when rated by MarketBeat users. Likewise, 67.09% of users gave Gossamer Bio an outperform vote while only 60.74% of users gave ZIVO Bioscience an outperform vote. CompanyUnderperformOutperformZIVO BioscienceOutperform Votes9960.74% Underperform Votes6439.26% Gossamer BioOutperform Votes15767.09% Underperform Votes7732.91% Is ZIVO or GOSS more profitable? ZIVO Bioscience's return on equity of 0.00% beat Gossamer Bio's return on equity.Company Net Margins Return on Equity Return on Assets ZIVO BioscienceN/A N/A -2,240.92% Gossamer Bio N/A -127.28%-22.12% Do institutionals & insiders hold more shares of ZIVO or GOSS? 12.8% of ZIVO Bioscience shares are owned by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are owned by institutional investors. 21.5% of ZIVO Bioscience shares are owned by company insiders. Comparatively, 6.7% of Gossamer Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryGossamer Bio beats ZIVO Bioscience on 12 of the 17 factors compared between the two stocks. Get ZIVO Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for ZIVO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZIVO vs. The Competition Export to ExcelMetricZIVO BioscienceBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$59.90M$2.95B$5.34B$8.46BDividend YieldN/A1.65%5.29%4.18%P/E Ratio-3.2231.6726.8719.78Price / Sales3,779.32420.24404.10138.41Price / CashN/A168.6838.2534.64Price / Book-19.403.216.774.54Net Income-$7.78M-$72.35M$3.22B$247.85M7 Day Performance-12.72%0.21%1.43%1.31%1 Month Performance-16.45%1.82%9.45%9.43%1 Year Performance96.87%-18.84%20.32%10.33% ZIVO Bioscience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZIVOZIVO BioscienceN/A$15.57-0.9%N/A+96.9%$59.38M$15,850.00-3.1910News CoverageGOSSGossamer Bio3.933 of 5 stars$1.20+3.4%$7.75+545.8%+95.1%$272.76M$124.59M-3.75180Analyst RevisionCADLCandel Therapeutics1.9321 of 5 stars$5.43+0.2%$21.00+286.7%-30.5%$272.06M$120,000.00-3.1460News CoverageOCGNOcugen1.0095 of 5 stars$0.93+1.8%$6.00+544.6%-48.3%$271.82M$4.52M-5.1780High Trading VolumeTSVT2seventy bio1.2586 of 5 stars$5.00flat$4.25-15.0%N/A$266.15M$48.37M-2.69440TERNTerns Pharmaceuticals4.101 of 5 stars$3.02+2.7%$15.63+417.4%-51.6%$263.76MN/A-2.5640Positive NewsPVLAPalvella Therapeutics3.917 of 5 stars$23.72+7.3%$46.29+95.1%N/A$262.25M$42.81M-1.96N/APositive NewsGap UpHigh Trading VolumeINZYInozyme Pharma3.0604 of 5 stars$3.96flat$11.75+196.7%-10.2%$255.67MN/A-2.5450LFCRLifecore Biomedical1.7977 of 5 stars$6.72+0.7%$8.00+19.0%+23.7%$248.81M$130.31M-12.00690News CoverageInsider TradeAVIRAtea Pharmaceuticals2.7395 of 5 stars$2.90+1.8%$6.00+106.9%-18.8%$248.18MN/A-1.4070Positive NewsNGNENeurogene3.3236 of 5 stars$17.28-4.2%$44.60+158.1%-44.3%$246.45M$925,000.00-3.9790Gap Down Related Companies and Tools Related Companies GOSS Alternatives CADL Alternatives OCGN Alternatives TSVT Alternatives TERN Alternatives PVLA Alternatives INZY Alternatives LFCR Alternatives AVIR Alternatives NGNE Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZIVO) was last updated on 5/29/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredAs Bitcoin supply vanishes, this Trump-aligned token could explodeBitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ZIVO Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ZIVO Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
